Literature DB >> 15716560

N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.

Charlotte Kragelund1, Bjørn Grønning, Lars Køber, Per Hildebrandt, Rolf Steffensen.   

Abstract

BACKGROUND: The level of the inactive N-terminal fragment of pro-brain (B-type) natriuretic peptide (BNP) is a strong predictor of mortality among patients with acute coronary syndromes and may be a strong prognostic marker in patients with chronic coronary heart disease as well. We assessed the relationship between N-terminal pro-BNP (NT-pro-BNP) levels and long-term mortality from all causes in a large cohort of patients with stable coronary heart disease.
METHODS: NT-pro-BNP was measured in baseline serum samples from 1034 patients referred for angiography because of symptoms or signs of coronary heart disease. The rate of death from all causes was determined after a median follow-up of nine years.
RESULTS: At follow-up, 288 patients had died. The median NT-pro-BNP level was significantly lower among patients who survived than among those who died (120 pg per milliliter [interquartile range, 50 to 318] vs. 386 pg per milliliter [interquartile range, 146 to 897], P<0.001). Patients with NT-pro-BNP levels in the highest quartile were older, had a lower left ventricular ejection fraction (LVEF) and a lower creatinine clearance rate, and were more likely to have a history of myocardial infarction, clinically significant coronary artery disease, and diabetes than patients with NT-pro-BNP levels in the lowest quartile. In a multivariable Cox regression model, the hazard ratio for death from any cause for the patients with NT-pro-BNP levels in the fourth quartile as compared with those in the first quartile was 2.4 (95 percent confidence interval, 1.5 to 4.0; P<0.001); the NT-pro-BNP level added prognostic information beyond that provided by conventional risk factors, including the patient's age; sex; family history with respect to ischemic heart disease; the presence or absence of a history of myocardial infarction, angina, hypertension, diabetes, or chronic heart failure; creatinine clearance rate; body-mass index; smoking status; plasma lipid levels; LVEF; and the presence or absence of clinically significant coronary artery disease on angiography.
CONCLUSIONS: NT-pro-BNP is a marker of long-term mortality in patients with stable coronary disease and provides prognostic information above and beyond that provided by conventional cardiovascular risk factors and the degree of left ventricular systolic dysfunction. Copyright 2005 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15716560     DOI: 10.1056/NEJMoa042330

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  142 in total

1.  Natriuretic peptides as markers of cardiovascular risk: the story continues.

Authors:  Hector O Ventura; Marc A Silver
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

2.  Prognostic value of B-type natriuretic peptide in surgical palliation of children with single-ventricle congenital heart disease.

Authors:  J G Berry; B Askovich; R E Shaddy; J A Hawkins; C G Cowley
Journal:  Pediatr Cardiol       Date:  2007-08-04       Impact factor: 1.655

Review 3.  Neurohormonal modulation in heart failure of ischemic etiology: correlates with left ventricular remodeling.

Authors:  Roberto Latini; Serge Masson; Lidia Staszewsky; Simona Barlera
Journal:  Curr Heart Fail Rep       Date:  2006-12

Review 4.  Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

Authors:  Irmgard Tegeder; Gerd Geisslinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-04       Impact factor: 3.000

5.  Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements.

Authors:  Robert H Christenson; W H Wilson Tang
Journal:  MedGenMed       Date:  2006-05-31

6.  How effective are rapid access chest pain clinics? Prognosis of incident angina and non-cardiac chest pain in 8762 consecutive patients.

Authors:  N Sekhri; G S Feder; C Junghans; H Hemingway; A D Timmis
Journal:  Heart       Date:  2006-06-21       Impact factor: 5.994

7.  Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia.

Authors:  George V Z Dedoussis; Sandy Maumus; John Skoumas; Despoina M Choumerianou; Christos Pitsavos; Christodoulos Stefanadis; Sophie Visvikis-Siest
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

8.  "Upstream markers" provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes.

Authors:  Peter A Kavsak; Dennis T Ko; Alice M Newman; Glenn E Palomaki; Viliam Lustig; Andrew R Macrae; Allan S Jaffe
Journal:  Clin Chim Acta       Date:  2007-10-03       Impact factor: 3.786

9.  B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis.

Authors:  Matthew A Roberts; Piyush M Srivastava; Neil Macmillan; David L Hare; Sujiva Ratnaike; Ken Sikaris; Francesco L Ierino
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

10.  Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality.

Authors:  Oludamilola W Oluleye; Aaron R Folsom; Vijay Nambi; Pamela L Lutsey; Christie M Ballantyne
Journal:  Ann Epidemiol       Date:  2012-12-08       Impact factor: 3.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.